Compare BZFD & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZFD | TLPH |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 37.9M |
| IPO Year | N/A | 2010 |
| Metric | BZFD | TLPH |
|---|---|---|
| Price | $0.70 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 200.2K | ★ 211.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | $0.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $292.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.38 |
| 52 Week High | $2.68 | $1.57 |
| Indicator | BZFD | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 30.34 | 38.42 |
| Support Level | N/A | $0.76 |
| Resistance Level | $0.84 | $1.03 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 26.66 | 11.92 |
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.